Management of antithrombotic treatment and bleeding disorders in patients requiring venous access devices: A systematic review and a GAVeCeLT consensus statement

Author:

Annetta Maria Giuseppina1,Bertoglio Sergio2ORCID,Biffi Roberto3ORCID,Brescia Fabrizio4ORCID,Giarretta Igor5,Greca Antonio La1,Panocchia Nicola6,Passaro Giovanna7ORCID,Perna Francesco8,Pinelli Fulvio9ORCID,Pittiruti Mauro1ORCID,Prisco Domenico10,Sanna Tommaso8,Scoppettuolo Giancarlo1

Affiliation:

1. Vascular Access Team, University Hospital “A.Gemelli,” Rome, Italy

2. University of Genova and IRCCS “San Martino,” Genova, Italy

3. Surgical Unit, Istituto Europeo di Oncologia, Milano, Italy

4. Anesthesia and Intensive Care, Centro di Riferimento Oncologico, Aviano, Italy

5. Internal Medicine, University Hospital “A.Gemelli,” Rome, Italy

6. Nephrology and Dialysis Unit, University Hospital “A.Gemelli,” Rome, Italy

7. Internal Medicine, Hospital “San Filippo,” Rome, Italy

8. Cardiology, University Hospital ‘A.Gemelli’, Rome, Italy

9. Anesthesia and Intensive Care, Careggi University Hospital, Firenze, Italy

10. Experimental and Clinical Medicine, Careggi University Hospital, Firenze, Italy

Abstract

Insertion of venous access devices (VAD) is usually considered a procedure with low risk of bleeding. Nonetheless, insertion of some devices is invasive enough to be associated with bleeding, especially in patients with previous coagulopathy or in treatment with antithrombotic drugs for cardiovascular disease. The current practices of platelet/plasma transfusion in coagulopathic patients and of temporary suspension of the antithrombotic treatment before VAD insertion are based on local policies and are often inadequately supported by evidence, since many of the clinical studies on this topic are not recent and are not of high quality. Furthermore, the protocols of antithrombotic treatment have changed during the last decade, after the introduction of new oral anticoagulant drugs. Though some guidelines address some of these issues in relation with specific procedures (port insertion, etc.), no evidence-based document covering all the aspects of this clinical problem is currently available. Thus, the Italian Group of Venous Access Devices (GAVeCeLT) has decided to develop a consensus on the management of antithrombotic treatment and bleeding disorders in patients requiring VADs. After a systematic review of the available evidence, the panel of the consensus (which included vascular access specialists, surgeons, intensivists, anesthetists, cardiologists, vascular medicine experts, nephrologists, infective disease specialists, and thrombotic disease specialists) has structured the final recommendations as detailed answers to three sets of questions: (1) which is an appropriate classification of VAD-related procedures based on the specific bleeding risk? (2) Which is the appropriate management of the patient with bleeding disorders candidate to VAD insertion/removal? (3) Which is the appropriate management of the patient on antithrombotic treatment candidate to VAD insertion/removal? Only statements reaching a complete agreement were included in the final recommendations, and all recommendations were offered in a clear and synthetic list, so to be easily translated into clinical practice.

Publisher

SAGE Publications

Subject

Nephrology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3